
|Videos|November 16, 2017
The Influence of the Gut Microbiome on Response to Anti-PD-1 Therapy in Melanoma
Author(s)Vancheswaran Gopalakrishnan, MPH
Vancheswaran Gopalakrishnan, MPH, a post-doctorate fellow in Dr. Jennifer Wargo's laboratory at The University of Texas MD Anderson Cancer Center, discusses a study that explored the diversity and composition of the gut microbiome in melanoma patients and its influence on response to anti-PD-1 therapy during The Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting. Dr. Gopalakrishnan completed this study under the mentorship of Dr. Wargo, who was the principal investigator.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































